COVID-19 Seroprevalence Study in French Guiana (EPI-COVID-POP)

Pasteur Institute

Status: Completed

Conditions: SARS-CoV Infection; Covid19; Severe Acute Respiratory Syndrome; Coronavirus Infection

Treatments: Procedure: Blood sample

Study type: Interventional

Funder types: Industry; Other

Identifiers

NCT04490850

2020-048

Details and patient eligibility

About

Serological surveys measuring anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies in the population to assess the extent of the infection and the COVID-19 immunity of the population in French Guiana.

Full description

Serological surveys measuring anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies in the population to assess the extent of the infection and the COVID-19 immunity of the population in French Guiana.

This study is a interventional study that present minimal risks and constraints.

The results of the study will allow estimation of COVID-19 virus infection, severity and attack rates, as well as inform public health responses and policy decisions in the French Guiana territory.

Enrollment: 3,541 patients

Sex: All

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Person going to a prevention and care center or medical biology analysis laboratory as part of the care, regardless age, regardless of an acute or previous infection with COVID-19;
• State of health compatible with a blood sample as defined in the protocol

Exclusion criteria

• Inability to consent
• Person under guardianship or curatorship
• Known pathology or a health problem contraindicated with the collect of blood sample.

Trial design

Primary purpose: Prevention

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

3,541 participants in 1 patient group

Participants

Experimental group

Description:

Blood sample

Treatment:

Procedure: Blood sample